Core Viewpoint - Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Pinterest, Inc. (NYSE: PINS) securities between February 7, 2025, and February 12, 2026, alleging that the company misled investors regarding its advertising revenues [1][2]. Allegations - The lawsuit claims that Pinterest failed to disclose significant issues affecting its advertising revenues, including reduced revenues from advertising partners and the impact of U.S. tariffs on its business operations [2]. - It is alleged that Pinterest overstated its ability to manage these macroeconomic challenges, leading to misleading public statements about its financial health [2]. Financial Performance - On February 12, 2026, Pinterest reported quarterly revenue of $1.32 billion, which was below the consensus estimate of $1.33 billion. The company also provided Q1 2026 revenue guidance of $951 million to $971 million, falling short of the consensus estimate of $980.6 million [3]. - CEO William Ready attributed the company's performance to "exogenous shock" related to tariffs, which disproportionately affected advertising spending from top retail advertisers. CFO Julia Donnelly indicated that these tariff-related headwinds are expected to continue and may worsen in Q1 [3]. Stock Impact - Following the announcement of disappointing financial results, Pinterest's stock price dropped by $3.12 per share, or 16.83%, closing at $15.42 on February 13, 2026 [3].

Core Viewpoint - A class action lawsuit has been filed against ImmunityBio, Inc. for allegedly misleading investors about its lead product candidate, Anktiva, during the period from January 19, 2026, to March 25, 2026 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Soon-Shiong, the defendant, materially overstated Anktiva's capabilities, leading to misleading impressions about its effectiveness [2]. - A warning letter from the U.S. Food and Drug Administration (FDA) was publicized on March 24, 2026, indicating that promotional communications created a misleading impression that Anktiva could cure and prevent all cancer [3]. - Following the FDA warning, ImmunityBio's stock price fell by $1.98 per share, or 21%, closing at $7.42 per share on March 24, 2026 [3]. Group 2: Legal Proceedings and Participation - Shareholders who wish to participate in the class action can contact Robbins LLP, and those interested in serving as lead plaintiffs are encouraged to reach out [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Company Background - ImmunityBio, Inc. is a biotechnology company, with Anktiva being its lead biologic product aimed at treating a specific type of bladder cancer [1].

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for allegedly misleading investors regarding its drug candidate tabelecleucel, which has faced regulatory challenges from the FDA [1][2]. Group 1: Allegations and Issues - The lawsuit claims that Atara failed to disclose significant manufacturing issues and deficiencies in the ALLELE study, which made FDA approval of tabelecleucel unlikely [2]. - It is alleged that the company overstated the regulatory prospects of tabelecleucel, leading to a heightened risk of regulatory scrutiny and jeopardizing ongoing clinical trials [2]. - The complaint indicates that these undisclosed issues were likely to have a significant negative impact on Atara's business and financial condition, rendering public statements materially false and misleading [2]. Group 2: Stock Price Impact - Following the announcement of a Complete Response Letter (CRL) from the FDA on January 12, 2026, Atara's stock price dropped by $7.79 per share, or 56.99%, closing at $5.88 per share [3]. Group 3: Class Action Participation - Shareholders who wish to participate in the class action against Atara Biotherapeutics can contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [4].

Core Viewpoint - Robbins LLP has announced a class action lawsuit against Coty Inc. on behalf of investors who acquired its common stock between November 5, 2025, and February 4, 2026, alleging that the company misled investors regarding its financial performance and growth outlook [1][2]. Allegations and Financial Performance - The lawsuit claims that during the class period, Coty misrepresented its growth prospects, suggesting strong performance due to new product launches and operational improvements while downplaying risks associated with a slowing beauty market [2]. - Following the announcement of disappointing financial results for the second quarter of fiscal year 2026, Coty revealed underperformance in its Consumer Beauty segment and withdrew its EBITDA guidance for the fiscal year 2026, leading to a significant stock price drop of approximately 22%, from $3.43 on February 4, 2026, to $2.66 on February 6, 2026 [3]. Company Background - Coty Inc. is involved in the manufacturing, marketing, distribution, and sale of branded beauty products globally, indicating its significant role in the beauty industry [1].

Core Viewpoint - A class action lawsuit has been filed against Power Solutions International, Inc. (NASDAQ: PSIX) for allegedly misleading investors about its business prospects during the period from May 8, 2025, to March 2, 2026 [1][2]. Allegations - The lawsuit claims that Power Solutions overstated its ability to meet sales demand for its power systems, particularly in the data center market [2]. - It is alleged that the company did not adequately disclose the impact of enhancements to its manufacturing capacity and the associated costs and inefficiencies [2]. - The positive statements made by the company regarding its business operations and prospects were claimed to be materially misleading [2]. Financial Impact - On March 2, 2026, Power Solutions announced its fourth quarter and full year 2025 financial results, revealing an 8% year-over-year decline in gross margin due to operational inefficiencies from an accelerated production ramp-up for data center products [3]. - The company projected only moderate margin improvement for 2026 and indicated that it was just beginning to see measurable improvements in supply chain performance and manufacturing cost structures [3]. - Following these disclosures, the stock price of Power Solutions fell by $24.84, or 28.97%, closing at $60.91 on March 3, 2026 [3].

Core Viewpoint - Robbins LLP is reminding investors of a pending class action lawsuit against Enphase Energy, Inc. for allegedly misleading investors regarding its inventory management and financial prospects during a specific period [1][2]. Group 1: Class Action Details - A class action was filed on behalf of all investors who purchased or acquired Enphase Energy, Inc. securities between April 22, 2025, and October 28, 2025 [1]. - The allegations include that Enphase overstated its ability to manage channel inventory and mitigate the effects of the termination of the 25D Credit, which allowed homeowners to deduct 30% of clean energy property costs [2]. Group 2: Financial Impact - On October 28, 2025, Enphase reported its third-quarter financial results, indicating expectations of a weak close to 2025 due to elevated channel inventory and lower battery storage shipments [3]. - Following this announcement, Enphase's stock price fell by $5.56 per share, or 15.15%, closing at $31.14 per share on October 29, 2025 [3]. Group 3: Shareholder Actions - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers to the court by April 20, 2026 [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4].

Core Viewpoint - Robbins LLP has announced a class action lawsuit against Gemini Space Station, Inc. for allegedly misleading investors regarding its initial public offering (IPO) and subsequent financial disclosures [1][2]. Group 1: Allegations and Misleading Information - The lawsuit claims that Gemini overstated the viability of its cryptocurrency platform and its commitment to expanding internationally, leading to inflated post-IPO financial prospects [2]. - The offering documents and public statements made by Gemini were allegedly materially false and misleading throughout the class period [2]. Group 2: Stock Performance and Corporate Changes - Following a blog post by the Winklevoss brothers on February 5, 2026, announcing significant operational changes, Gemini's Class A common stock price dropped by $0.64, or 8.72%, closing at $6.70 per share [3]. - On February 17, 2026, Gemini reported preliminary unaudited financial results for the fiscal year ended December 31, 2025, with net revenue estimated between $165 million and $175 million and operating expenses projected to be $520 million to $530 million, marking a 40% increase from the previous year. This announcement led to a further decline in stock price by $0.975, or 12.9%, closing at $6.585 per share [4].

Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the likelihood of FDA approval for its leading drug candidate, AMT-130, during the period from September 24, 2025, to October 31, 2025 [2][3]. Group 1: Allegations and Impact - Robbins LLP is investigating allegations that uniQure misled investors about the FDA approval likelihood of AMT-130, claiming that the design of the pivotal study was not fully approved by the FDA and that the company downplayed the need for additional studies [2]. - On November 3, 2025, uniQure announced that the FDA no longer agreed that the data from the Phase I/II studies were adequate for a Biologics License Application (BLA) submission, leading to a significant stock price drop of $33.40 per share, or over 49%, from $67.69 to $34.29 [3]. Group 2: Shareholder Actions - Shareholders may be eligible to participate in the class action and must submit their papers to the court by April 13, 2026, if they wish to serve as lead plaintiffs [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 3: Legal Representation - Robbins LLP operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless the case is won [5]. - The firm has a history of advocating for shareholder rights and aims to help recover losses and improve corporate governance [5].

Core Viewpoint - Robbins LLP has filed a class action lawsuit on behalf of investors who purchased Gartner, Inc. common stock between February 4, 2025, and February 2, 2026, alleging that the company misled investors regarding its growth and projected revenue [1][2]. Allegations - The lawsuit claims that during the class period, Gartner provided materially misleading information about its expected contract value (CV) growth and projected revenue for fiscal year 2025 while concealing adverse facts about its actual growth rates [2]. - Gartner's claims of achieving 12-16% CV growth rates in a normal macroeconomic environment were deemed unrealistic, leading to shareholders purchasing securities at artificially inflated prices [2]. Disclosure of Truth - The truth about Gartner's performance emerged on February 3, 2026, when the company announced a significant decline in its CV growth rate, which fell by 2%, and disclosed a shortfall in its Consulting segment's performance against internal projections [3]. - Following this announcement, Gartner's stock price dropped from $202.40 per share on February 2, 2026, to $160.16 per share on February 3, 2026, marking a decline of nearly 20.87% in one day [3]. Next Steps for Investors - Shareholders interested in participating in the class action or serving as lead plaintiff are encouraged to contact Robbins LLP [4]. - Investors can choose to remain absent class members if they do not wish to take action [4]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Robbins LLP has announced a class action lawsuit against Eos Energy Enterprises, Inc. for allegedly misleading investors about its business prospects during a specific period [1] Group 1: Allegations Against Eos Energy - The lawsuit claims that Eos Energy failed to disclose its inability to achieve production and capacity utilization targets necessary to meet previously set revenue guidance [1] - It is alleged that the company's battery line downtime was significantly higher than industry norms and internal forecasts [1] - The complaint states that Eos Energy faced delays in meeting quality targets for its automated bipolar production, which contributed to rework and lost revenue [1] Group 2: Financial Performance - Eos Energy reported a full year 2025 revenue of $114.2 million, which was below the previously issued guidance of $150 million to $160 million [1] - The company experienced a gross loss of $143.8 million and a net loss attributable to shareholders of $969.6 million for the same period [1] - An adjusted EBITDA loss of $219.1 million was also reported, indicating significant financial challenges [1] Group 3: Market Reaction - Following the announcement of disappointing financial results, Eos Energy's stock price fell by $4.39, or 39.4%, closing at $6.74 per share on February 26, 2026 [1]